Try
Zymeworks Inc.
ZYMEUnited States
21 filed reports · 337 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
21 reports · Sep 2022 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 8 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 12 | 2,264 | Sep 2022 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 4 | 2,211 | Dec 2022 to Dec 2025 |
| Current · 8-KSEC EDGAR | 4 | 8 | Dec 2022 to Jun 2023 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 358 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 215 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 2, 2026 | 964 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 277 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 182 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 182 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 5, 2025 | 456 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 31, 2024 | 174 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 142 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 2, 2024 | 140 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 6, 2024 | 435 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 7, 2023 | 170 | Open |
Financial data
337 concepts · 4,484 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial318 concepts · 4,157 facts · Jun 2018 to Aug 2026
- Operating lease liability32 · Dec 2021 to Jun 2026
- Stockholders equity (US GAAP)29 · Dec 2020 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value28 · Dec 2020 to Jun 2026
- Net income loss28 · Dec 2020 to Jun 2026
- Stock issued during period value stock options exercised28 · Dec 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents27 · Dec 2020 to Jun 2026
- Adjustment for change in fair value of liability classified stock options26 · Dec 2020 to Jun 2026
- Comprehensive income net of tax26 · Dec 2020 to Jun 2026
- Costs and expenses26 · Dec 2020 to Jun 2026
- General and administrative expense (US GAAP)26 · Dec 2020 to Jun 2026
- Income tax expense benefit26 · Dec 2020 to Jun 2026
- Interest income expense nonoperating net26 · Dec 2020 to Jun 2026
- Net income loss available to common stockholders basic26 · Dec 2020 to Jun 2026
- Net income loss available to common stockholders diluted26 · Dec 2020 to Jun 2026
- Nonoperating income expense26 · Dec 2020 to Jun 2026
- Operating income loss26 · Dec 2020 to Jun 2026
- Revenue26 · Dec 2020 to Jun 2026
- Amortization of intangible assets25 · Dec 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect25 · Dec 2020 to Jun 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents25 · Dec 2020 to Jun 2026
- Foreign currency transaction gain loss unrealized25 · Dec 2020 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities25 · Dec 2020 to Jun 2026
- Increase decrease in accounts receivable25 · Dec 2020 to Jun 2026
- Increase decrease in deferred income taxes25 · Dec 2020 to Jun 2026
Segment16 concepts · 280 facts · Dec 2022 to Jun 2026
- Research and development expense84 · Dec 2022 to Dec 2025
- Research and development expense excluding acquired in process cost28 · Mar 2025 to Jun 2026
- Labor and related expense14 · Dec 2022 to Jun 2026
- Other research and development expense14 · Dec 2022 to Jun 2026
- Allocated share based compensation expense12 · Dec 2022 to Dec 2025
- Costs and expenses12 · Dec 2022 to Dec 2025
- Depreciation depletion and amortization12 · Dec 2022 to Dec 2025
- Income tax expense benefit12 · Dec 2022 to Dec 2025
- Interest income expense nonoperating net12 · Dec 2022 to Dec 2025
- Net income loss12 · Dec 2022 to Dec 2025
- Nonoperating income expense12 · Dec 2022 to Dec 2025
- Operating income loss12 · Dec 2022 to Dec 2025
- Other general and administrative expense12 · Dec 2022 to Dec 2025
- Revenue12 · Dec 2022 to Dec 2025
- Business combination contingent consideration arrangements change in amount of contingent consideration liability110 · Dec 2022 to Dec 2025
- Research and development asset acquired other than through business combination written off10 · Dec 2022 to Dec 2025
Product2 concepts · 39 facts · Dec 2020 to Dec 2025
- Revenue21 · Dec 2020 to Dec 2025
- CEWS and CERS subsidies18 · Dec 2020 to Dec 2023
Guidance1 concepts · 8 facts · Jan 2023 to Aug 2023
- Capital Expenditures Guidance8 · Jan 2023 to Aug 2023
Segments
319 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 280 facts
- Reportable280 · Dec 2022 to Jun 2026
Product or service6 members · 39 facts
- Research Support Payments And Other Service21 · Dec 2020 to Dec 2025
- Grant4 · Dec 2020 to Dec 2023
- Grant CEWS And Rent Subsidy4 · Dec 2020 to Dec 2023
- SRED Credits4 · Dec 2020 to Dec 2023
- Canada Emergency Rent Subsidy3 · Dec 2021 to Dec 2023
- Canada Emergency Wage Subsidy3 · Dec 2021 to Dec 2023
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.